Research Scientist II, High Throughput Chemistry at Axsome Therapeutics Inc

San Diego, California, United States

Apply Now

$123,000 – $154,000Compensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Ph.D. degree in Organic Chemistry with 2-5 years of industry experience or Master of Science (MS) degree in Organic Chemistry with 8+ years of industry experience in synthetic organic chemistry
Strong command of modern organic synthetic methods
Direct hands-on experience with High Throughput Chemistry and/or Parallel Synthesis
Experience with laboratory automation, liquid handling robotics, and automated analytical and purification systems
Ability to thrive in fast-paced, highly collaborative, and dynamic research environment
Excellent written and verbal communication skills; must be able to articulate complex scientific concepts, technical challenges, and results clearly and concisely to diverse audiences
Proven ability to thrive in a fast-paced, high-volume environment where priorities and synthetic targets may shift rapidly based on biological data
Strongly Preferred: Experience with Direct-to-Biology (D2B) strategies for drug discovery
Strongly Preferred: Familiarity with the principles of medicinal chemistry
Strongly Preferred: Ability to mentor junior scientists

Responsibilities

Design and execute parallel synthetic methods to generate large, high-quality compound libraries
Identify, develop, and optimize novel synthetic methodologies with a focus on automation compatibility and HTE scalability
Apply newly developed synthetic routes from traditional bench-scale chemistry to robust, high-throughput, and automated processes
Oversee the operation, maintenance, and continuous advancement of our chemistry toolkit and automated synthesis equipment
Analyze research outcomes and library compound data and clearly communicate results and findings to cross-functional project teams
Ensure all laboratory work is conducted in accordance with established safety protocols and best laboratory and ELN data recording practices
Strong commitment to teamwork and the ability to function effectively as a core member of an interdisciplinary scientific team (chemistry, biology, software, and automation)
Proactive problem-solving mindset leveraging attention to detail and available resources to identify bottlenecks, troubleshoot automated processes, and develop solutions to ensure business continuity

Skills

Organic Synthesis

Catalysis

Reaction Development

High-Throughput Experimentation

HTE

Automated Synthesis

Parallel Synthesis

Synthetic Methodology

Laboratory Automation

ELN

Data Analysis

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free